Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600239 | 0.95 | DRD2 (0.66) | DRD2DRD3 | |
| SCHEMBL2232549 | 0.95 | DRD2 (0.67) | DRD2DRD3 | |
| SCHEMBL392228 | 0.91 | DRD2 (0.56) | DRD2DRD3 | |
| SCHEMBL4767228 | 0.88 | DRD2 (0.66) | DRD2DRD3 | |
| SCHEMBL7450768 | 0.88 | DRD2 (0.67) | DRD2DRD3 | |
| SCHEMBL8205951 | 0.88 | DRD2 (0.66) | DRD2DRD3 | |
| SCHEMBL2347632 | 0.87 | DRD2 (0.67) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2347036 | 0.87 | DRD2 (0.64) | DRD2DRD3 | |
| SCHEMBL6179942 | 0.84 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL6601712 | 0.83 | DRD2 (0.68) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751116-B1 | Pyrimidine compounds and use thereof in the treatment of central nervous system disorders | ABBOTT GMBH & CO KG (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-1817037-B1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8268815-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-04-19 | — | — | US | disclosed |
| US-8101754-B2 | e.g., 2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-(1-methylcyclopropyl)-pyrimidine hydrochloride; central nervous system disorders; schizophrenia; antidepressant, anxiolytic agent, cognition activator; Parkinson's and Alzheimer's diseases | ABBOTT GMBH & CO. KG (DE) | 2012-01-24 | — | — | US | disclosed |
| EP-1003728-B1 | 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate | ABBOTT GMBH & CO KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2361908-A1 | Pyrimidine compounds useful for the treatment of CNS diseases | Abbott GmbH & Co. KG (DE) | 2011-08-31 | — | — | EP | disclosed |
| US-8008488-B2 | Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2272833-A1 | 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyridin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-1484330-B1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO KG (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-6919342-B2 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108706-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1484330-A1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-6486162-B2 | FOR THERAPY OF DISORDER OF THE CENTRAL NERVOUS SYSTEM WHICH RESPONDS TO DOPAMINE D3 LIGANDS SUCH AS SCHIZOPHRENIA, DEPRESSION, NEUROSES AND PSYCHOSES | ABBOTT LABORATORIES | 2002-11-26 | — | — | US | disclosed |
| US-6472392-B1 | Triazole compounds and the use thereof as dopamine-D3 -ligands | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| US-20020143179-A1 | 2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-10-03 | — | — | US | disclosed |
| EP-0994865-B1 | TRIAZOLE COMPOUNDS AND THE USE THEREOF AS DOPAMINE-D 3-LIGANDS | BASF AG (DE) | 2002-03-06 | — | — | EP | disclosed |
| US-20010020022-A1 | 2{3-[4-(2-T-BUTYL-6-TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARATE | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143179-A1 | 2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate | SLC6A3, DRD2, DRD3 | DRD2 2/4885DRD3 3/4885 |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | DRD3, SLC6A3, DRD2 | DRD2 3/4885DRD3 1/4885 |
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ADRB3, DRD3, ADORA3 | DRD2 9/4885DRD3 2/4885 |
| US-20010020022-A1 | 2{3-[4-(2-T-BUTYL-6-TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARATE | SLC6A3, DRD2, DRD3 | DRD2 2/4885DRD3 3/4885 |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, MC2R | DRD2 72/4885DRD3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.